Amphista Presents Preclinical Data, Advances Targeted Protein Degradation Pipeline
Event summary
- Amphista Therapeutics presented preclinical data at AACR 2026 on its SMARCA2 and TEAD Targeted Glue™ degrader programs.
- The company published initial data on its TEAD program in bioRxiv, detailing optimization of early Targeted Glues.
- SMARCA2 data demonstrated in vivo degradation and suppression of downstream biomarkers following oral dosing.
- TEAD data showed anti-proliferative activity in mesothelioma cell lines and synergistic efficacy with osimertinib in an EGFR-mutant NSCLC model.
- Amphista aims to select candidate molecules for its SMARCA2 and TEAD programs in the second half of 2026.
The big picture
Amphista’s work contributes to the growing field of targeted protein degradation, a novel therapeutic modality aiming to overcome limitations of traditional small molecules. The company’s focus on non-cereblon/non-VHL degraders differentiates it from competitors and addresses potential immunogenicity concerns. Success in this area could unlock new treatment options for cancers and neurodegenerative disorders, representing a significant market opportunity.
What we're watching
- Clinical Translation
- The ability to translate these promising preclinical results into effective clinical candidates will be crucial for Amphista's long-term success, particularly given the challenges inherent in degrader development.
- Partnering Strategy
- Amphista's stated intention to seek partners suggests a resource constraint or a strategic decision to de-risk development; the terms and scope of any such collaborations will be key indicators of the programs’ perceived value.
- Selectivity Risk
- While the data highlights SMARCA2 selectivity, maintaining this selectivity over time in vivo, as demonstrated, remains a critical factor to avoid off-target effects and ensure therapeutic safety.
Related topics